PTSD Patients in TXOG Focus Group Unanimously Report Symptom Relief Through Medical Cannabis

CANNANNEW REPORT

Texas Original Compassionate Cultivation assembled a focus group of veterans suffering from PTSD to evaluate symptom response, product preference and effects on supplemental pharmaceutical consumption AUSTIN, Texas–(BUSINESS WIRE)–Texas Original Compassionate Cultivation (TXOG), Texas’ leading medical cannabis provider, today released results from its post-traumatic stress disorder (PTSD) focus group detailing the positive effects of medical cannabis use. The focus group consisted of veterans suffering from PTSD who qualify for medical cannabis under the expanded Compassionate Use Program. Notably, 100% of the focus group participants reported they experienced relief from their symptoms associated with PTSD with TXOG’s product. This response reflects recent peer-reviewed studies from Wayne State University and the Federal University of Paraná that reported lower threat-related amygdala reactivity and suppressed anxiety in PTSD patients using medical cannabis. “Many veterans in Texas and around the country face a much different enemy when they return home, one who is invisible but no less dangerous,” said Morris Denton, CEO of TXOG. “Medical cannabis plays a critical role in many of those veterans’ lives. TXOG stands committed to being an ally in that fight by doing whatever we can to not only help them find symptom relief, but to continue to drive the expansion of medical cannabis legislation that enhances accessibility for more veterans and other Texans suffering from PTSD.” Focus group participants sampled TXOG’s gummy, lozenge and tincture products at various dosages based on prescriptions from their physicians. Patients overwhelmingly reported a quick product onset, with 77% and 62% of participants experiencing an onset within 30 minutes for gummies and tinctures, respectively. Eighty-five percent of participants also reported they were mostly or very satisfied with the product’s onset. Notably, more than 60% of participants reported a preference for TXOG’s gummy products, which are available in a 0:1 THC-only formulation as well as a…

Excerpt only …
READ MORE BELOW
Source : PTSD Patients in TXOG Focus Group Unanimously Report Symptom Relief Through Medical Cannabis

reposted by Cannabis News World

This site uses Akismet to reduce spam. Learn how your comment data is processed.